ALPROLIX ® is the first extended half-life (EHL) factor IX therapy for hemophilia B. Since 2014, ALPROLIX has had over 10 years of experience across ages and settings.

Mar 28, 2014 · Biogen Idec plans to make ALPROLIX commercially available to people with hemophilia B in the United States in early May. To help address the hemophilia B community’s needs, Biogen Idec is …

Product approval information is indicated for adults and children with hemophilia B for: (1) On-demand treatment and control of bleeding episodes, (2) Perioperative management, (3) Routine ...

ALPROLIX is a recombinant, fusion protein that temporarily replaces the missing coagulation Factor IX needed for effective hemostasis. ALPROLIX contains the Fc region of human IgG1, which binds to the …

ALPROLIX has more than 10 years of experience with hemophilia B patients across ages and settings 1-3 ALPROLIX is a recombinant DNA derived, coagulation Factor IX concentrate indicated in adults and …

May 13, 2024 · Alprolix is used in hemophilia B to help control and prevent bleeding, it is a coagulation Factor IX replacement. Includes Alprolix administration, uses, side effects, and dose.

Alprolix is indicated for adults and children with hemophilia B for episodic treatment and control of bleeding, as well as for perioperative management of bleeding and prophylactic treatment. 1 Alprolix …

Sep 28, 2023 · Alprolix is the first approved therapy to prevent and control bleeds in adults and children with hemophilia B.

ALPROLIX, Coagulation Factor IX (Recombinant), Fc Fusion Protein, is a recombinant DNA derived coagulation Factor IX concentrate indicated in adults and children with hemophilia B (congenital ...

Biogen Idec leads development for Alprolix, has manufacturing rights, and has commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Sobi Sobi is an …